Search
Human papillomavirus type 11 L1 capsid protein antigen
go.drugbank.com/drugs/DB10300ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTIONPhenytoin
go.drugbank.com/drugs/DB00252ApprovedInvestigationalVet approved[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications … [A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein substratesSynonyms: PR-122 (redox-phenytoin)Idoxuridine
go.drugbank.com/drugs/DB00249ApprovedWithdrawnAn analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseZuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalZuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesHuman papillomavirus type 6 L1 capsid protein antigen
go.drugbank.com/drugs/DB10299ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 6 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTIONSodium stibogluconate
go.drugbank.com/drugs/DB05630ApprovedInvestigationalWidespread resistance has limited the utility of sodium stibogluconate, and in many parts of the world, amphotericin or miltefosine are used instead. … It is also being investigated as an anti-tumor agent.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalIt was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … [A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVecabrutinib
go.drugbank.com/drugs/DB16657InvestigationalVecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).
Fosdenopterin
go.drugbank.com/drugs/DB16628Approved[A230088,L32163] Patients with MoCD may present with metabolic acidosis, intracranial hemorrhage, feeding difficulties, and significant neurological symptoms such as muscle hyper- and hypotonia, intractable … In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended fosdenopterin be granted marketing authorization under exceptional circumstances for the treatment of patients
Brilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. … It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]